tbuckley/cabot-search huggingface dataset:
The Diagnosis of Hypertrophic Subaortic Stenosis with a Doppler Velocity Flow Detector.
Authors: Frank S. Harrison
Journal: Annals of Internal Medicine (1970)

Meeting Abstracts1 May 1970The Diagnosis of Hypertrophic Subaortic Stenosis with a Doppler Velocity Flow Detector.Frank S. Harrison Jr., M.D., Claude R. Joyner Jr., F.A.C.P.Frank S. Harrison Jr., M.D.Search for more papers by this author, Claude R. Joyner Jr., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-72-5-783_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPrevious studies using an aortic electromagnetic flowmeter at surgery or the intra-aortic catheter pressure gradient technique have indicated a characteristic phasic flow pattern of rapid, early systolic ejection and reduced, late systolic ejection in individuals with hypertrophic subaortic stenosis. A transcutaneous Doppler velocity probe was used in the study of 10 individuals with proved hypertrophic subaortic stenosis to determine if a pattern of flow similar to that described by other techniques could be recorded and to evaluate the possible application of this external method for the diagnosis of hypertrophic subaortic stenosis. Hoppler velocity recordings of carotid flow were obtained simultaneously... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Frank S. HarrisonJr., M.D.; Claude R. JoynerJr., F.A.C.P.Affiliations: Philadelphia, Pa. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1970Volume 72, Issue 5Page: 783-783KeywordsCathetersStenosisSurgery ePublished: 1 December 2008 Issue Published: 1 May 1970 PDF downloadLoading ...
Toxic Metals in Aquatic Ecosystems: A Microbiological Perspective
Authors: Timothy Ford, David Ryan
Journal: Environmental Health Perspectives (1995)

Microbe-metal interactions in aquatic environments and their exact role in transport and transformations of toxic metals are poorly understood.This paper will briefly review our understanding of these interactions.Ongoing research in Lake Chapala, Mexico, the major water source for the City of Guadalajara, provides an opportunity to study the microbiological aspects of metal-cycling in the water column.Constant resuspension of sediments provides a microbiologically rich aggregate-based system.Data indicate that toxic metals are concentrated on aggregate material and bioaccumulate in the food chain.A provisional model is presented for involvement of microbial aggregates in metal-cycling in Lake Chapala.
MARRIAGE AS A REMEDY.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Text-Book of Human Anatomy, Systematic and Topographical, including the Embryology, Histology and Morphology of Man, with special reference to the requirements of Practical Medicine and Surgery.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increased cardiac fatty acid uptake with dobutamine infusion in swine is accompanied by a decrease in malonyl CoA levels
Authors: J. L. Hall, G. D. Lopaschuk, A. Barr, J. Bringas, R. D. Pizzurro, W. C. Stanley
Journal: Cardiovascular Research (1996)

Malonyl CoA is an important regulator of fatty acid oxidation in the heart secondary to its ability to inhibit carnitine palmitoyltransferase 1 (CPT 1). Malonyl CoA is produced from acetyl CoA in a reaction catalyzed by acetyl CoA carboxylase (ACC). In this study we determined if alterations in malonyl CoA regulation of fatty acid metabolism are involved in the increase in energy transduction seen following an increase in cardiac work. Methods: Anesthetized, open-chest, domestic swine were subjected to a 30 min control period followed by a 30 min treatment period with either dobutamine (15 μg · kg−1 · min−1 i.v.) (n = 6) or saline (n = 6). Results: Heart rate, left ventricular peak dp/dt, and MVO2, were significantly increased in the dobutamine group compared to the saline group during the treatment period. Free fatty acid and glucose uptake were increased 210 and 248%, respectively, in the dobutamine group during the treatment period. Malonyl CoA content was decreased by 55% (from 0.40 ± 0.05 to 0.18 ± 0.12 nmol/g wet wt; P < 0.05) with dobutamine treatment, but was not affected by saline treatment. ACC activity was not significantly different between groups (0.31 ± 0.02 vs. 0.30 ± 0.04 nmol · min−1 · mg protein−1, respectively). The activity of AMP-dependent protein kinase (AMPK), which phosphorylates and inactivates ACC, was also not significantly different in the dobutamine hearts compared to the saline hearts (322 ± 26 vs. 338 ± 39 pmol · min−1 · mg protein−1, respectively). Conclusion: The increased cardiac work following dobutamine infusion is accompanied by a decrease in malonyl CoA levels and an increase in fatty acid uptake. However, the decrease in malonyl CoA cannot be explained by a decrease in ACC activity.
The risk of malignant melanoma, internal malignancy and mortality in xeroderma pigmentosum patients
Authors: J.S.C. English, A.J. Swerdlow
Journal: British Journal of Dermatology (1987)

Published evidence on malignancy and mortality of patients with xeroderma pigmentosum (XP) has come from aggregation of literature case reports or from patients known to particular clinical facilities. It is generally assumed that XP patients have a high mortality from actinic‐induced cutaneous tumours in the second and third decades.1 Such patients are likely to be selected, and hence biased. Also, previously reported studies have not given estimates of the level of age specific, and hence overall, risk of malignancy and mortality in XP. Follow‐up could give such estimates, but no follow‐up studies have yet been published. We have followed up a series of 27 XP patients. They have been followed for an average of 217 person‐years using the National Health Service Central Register, hospital case records and correspondence with referring physicians; a further five patients had incomplete follow‐up Three patients developed malignant melanomas, but none developed internal malignancy. Two males and one female died [standardized mortality ratio (SMR) = 971, P < 0.05, for males; SMR= 1931, not significant, for females]. All three deaths were from non‐malignant causes: severe neurological involvement with terminal infection. This high mortality from neurological complications in XP patients contrasts with previously reported mortality, particularly from actinic‐induced cutaneous tumours.
Relation of Pediatric Blood Lead Levels to Lead in Gasoline
Authors: I. H. Billick, A. S. Curran, D. R. Shier
Journal: Environmental Health Perspectives (1980)

Analysis of a large data set of pediatric blood lead levels collected in New York City (1970-1976) shows a highly significant association between geometric mean blood lead levels and the amount of lead present in gasoline sold during the same period. This association was observed for all age and ethnic groups studied, and it suggests that possible exposure pathways other than ambient air should be considered. Even without detailed knowledge of the exact exposure pathways, sufficient information now exists for policy analysis and decisions relevant to controls and standards related to lead in gasoline and its effect on subsets of the population.
Operative Oral Surgery
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adult Congenital Heart Disease
Authors: Craig H. Scott
Journal: Annals of Internal Medicine (1998)

Medical Writings15 December 1998Adult Congenital Heart DiseaseCraig H. Scott, MDCraig H. Scott, MDUniversity of Pennsylvania, Philadelphia, PennsylvaniaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-12-199812150-00045 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Adult Congenital Heart Disease; Webb GD, Connelly MS, Somerville J, Warnes CA. Philadelphia: Lippincott-Raven; 1998. Single-user price, $295.00. Order phone 800-638-3030.Field of medicine: Adult and pediatric cardiovascular medicine.Format: CD-ROM software program.System requirements: Windows 3.1 or higher, 8 MB of RAM, 11 MB of free hard disk space; or Macintosh system 7.1 or higher, 8 MB of RAM, 8 MB of free hard disk space.Audience: Adult and pediatric cardiovascular specialists, fellows in cardiovascular training programs, and generalist physicians.Purpose: To review cardiac congenital disease by using a case example format linked to the Canadian Cardiovascular Society's consensus ... Author, Article, and Disclosure InformationAuthors: Craig H. Scott, MDAffiliations: University of Pennsylvania, Philadelphia, Pennsylvania PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 December 1998Volume 129, Issue 12Page: 1084KeywordsCongenital heart defectsCongenital heart diseaseDiagnostic radiologyElectrocardiographyHeart diseasesLibrariesLongitudinal studiesProspective studiesRetrospective studiesThorax ePublished: 15 August 2000 Issue Published: 15 December 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
From the NIH: Early-treatment diabetic retinopathy study. Patient recruitment under way
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Saturated fat is not the major issue
Journal: BMJ (2014)

f6340) by Aseem Malhotra stated that a recent "real world" study of 150 000 patients who were taking statins showed "unacceptable" side effects-including myalgia, gastrointestinal upset, sleep and memory disturbance, and erectile dysfunction-in 20% of participants.The author withdraws this statement.Although it was based on statements in the referenced observational study by Zhang and colleagues that "the rate of reported statin-related events to statins was nearly 18%," 1 the article did not reflect necessary caveats and did not take sufficient account of the uncontrolled nature of the study.
The Yellow Fever Microbe.
Authors: None R. S. W.
Journal: JAMA (1898)

New Orleans, La., Jan. 22, 1898. <h3>To the Editor:</h3> —<i>New Orleans Medical and Surgical Journal</i>for February, 1898, will contain an article upon the "Serum Diagnosis of Yellow Fever," by Archmaid and Woodson of New Orleans, La. These observers, working in the laboratory of the Louisiana State Board of Health, report the occurrence of a characteristic agglutinative reaction of yellow fever blood with the bacillus icteroides in over 70 per cent. of a series of fifty cases with which the experiments were conducted. They consider the reaction of decided value in the diagnosis of early mild and atypic cases. Yours very truly,
Professionalism vs Commercialism in Managed Care: The Need for a National Council on Medical Care-Reply
Authors: Francis D. Moore
Journal: JAMA (1997)

<h3>In Reply.</h3> —Dr Murray-Garcia reemphasized that some physicians have acted with unprofessional greed in the past. In our article we clearly recognize the shortcomings of our medical history. All of us concerned with the problems of corporate medicine are well advised to recall that the corporate forprofit world of pharmaceuticals and hospital supply has coexisted with physicians, hospitals, and patients for about 200 years. We have suggested no change in this complex commercial relationship. Certainly we should have emphasized the threats to the care of minorities in our discussion of enrollment exclusion in the world of medical care. Dr Vietzke is strongly opposed to any accommodation to our guidelines for commerce as it invades US medicine. We believe this simplistic approach to be an abandonment of our patients' trust, and unfair to them, their children, and their children's children, as well as the future of US medical care. If we refuse to
ORTHOPEDIC SURGERY
Authors: Leonard F. Peltier
Journal: JAMA (1965)

In the field of orthopedic surgery there are standard works which regularly appear, refurbished, in new editions; there are newer books bidding to become such fixtures; and there are the monographs expressing an individual point of view or summarizing the present state of our knowledge on particular subjects. All of these different categories are represented in the present review. <h3>General</h3> With the aid of collaborators, Shands has made the latest edition<i>of Handbook of Orthopaedic Surgery</i>(R. Shands, Jr. and R. B. Raney, with the collaboration of H. R. Brashear, ed 6, Mosby, 1963, $11.50) equal to its predecessors. It is still the best single volume on the subject. Ideally suited for students, it is here that it finds its greatest usefulness.<i>Orthopaedic Surgery</i>(Sir W. Mercer and R. B. Duthie, ed 6, Williams &amp; Wilkins, 1964, $24.50) also appears with a new collaboration. This book, originally wholly British, is
Myxomatosis
Authors: C. H. Andrewes
Journal: BMJ (1966)

<h3>AIMS</h3> To determine whether macrophage migration inhibitory factor (MIF) levels were increased in sera of the patients with iridocyclitis. <h3>METHODS</h3> Sera were obtained from 41 patients with acute iridocyclitis, 13 patients with chronic iridocyclitis, and 44 healthy control subjects. MIF levels were determined by a human MIF ELISA. <h3>RESULTS</h3> The average levels of MIF in the sera of patients with both acute and chronic iridocyclitis were significantly higher than that of healthy subjects. <h3>CONCLUSION</h3> Uveitis induces the elevation of serum MIF, which may affect various inflammatory symptoms in uveitis.
RIO DE JANEIRO
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Figure 3
Authors: David Barlow, Matthew Gallagher, Todd Farchione
Journal: JAMA Psychiatry (2017)

Bruce L. Rollman, MD, MPH; Bea Herbeck Belnap, Dr Biol Hum; Kaleab Z. Abebe, PhD; Michael B. Spring, PhD; Armando J. Rotondi, PhD; Scott D. Rothenberger, PhD; Jordan F. Karp, MD
IS SALICYLIC ACID AS A FOOD PRESERVATIVE HARMFUL?
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).
Authors: Jianjun Gao, Jose A. Karam, Nizar M. Tannir, Matthew T Campbell, Rebecca Slack Tidwell, Kamran Ahrar, Priya Rao, Chaan S. Ng, Eric Jonasch, Surena F. Matin, Amado J. Zurita, Amishi Yogesh Shah, Yu Shen, Jorge M. Blando, Luis M. Vence, Sreyashi Basu, Hao Zhao, James Patrick Allison, Christopher G. Wood, Padmanee Sharma
Journal: Journal of Clinical Oncology (2019)

4501 Background: Cytoreductive surgery (CS) including cytoreductive nephrectomy and metastasectomy provides clinical benefits to patients with MRCC. However, CS has not been evaluated in the setting of immune checkpoint (IC) therapy. We performed a pre-surgical/biopsy trial to evaluate biological and clinical activity of nivo +/- (bev or ipi) in patients with MRCC. Methods: In this open-label, randomized trial (NCT02210117), patients with MRCC w/o prior IC therapy and anti-VEGF therapy were randomized 2:3:2 to receive nivo (3mg/kg q2wks x3), nivo + bev (10mg/kg q2wks x3) or nivo + ipi (1mg/kg q3wks x2), followed by CS or Bx, and then nivo maintenance therapy up to 2 yrs. Clinical response per RECIST criteria was assessed at ≥12 wks. Pre- and post-treatment blood and tumors were obtained for correlative studies. Results: All of 105 patients have been accrued and 104 are evaluable for response. For all patients, best overall response (BOR = complete response [CR] + partial response [PR]) including surgery effect was 55% nivo, 44% nivo + bev, 43% nivo + ipi. Median PFS (95% confidence interval) was 14.5 months (5.5, not reached [NR]) nivo, 7.6 (4.8, 8.9) months nivo + bev, 7.5 (2.0, 12.4) months nivo + ipi. Overall survival (OS) at one year was 86% nivo, 73% nivo + bev, 83% nivo + ipi. Grade 3 or higher toxicities related to therapy were 38% for nivo, 42% for nivo + bev (including 18% hypertension), and 47% for nivo + ipi. For patients with CS, BOR including surgery effect was: 86% nivo, 88% nivo + bev, and 69% nivo + ipi. Median PFS was 17.3 months (6.1, NR) nivo, 7.6 (5.7, 10.3) months nivo + bev, 8.9 (2.9, 23.0) months nivo + ipi. OS at one year was 100% nivo, 94% nivo + bev, 92% nivo + ipi. Median OS has not yet reached with a median follow-up of 24.6 months. Immune and gene profiling analyses demonstrate: 1) tumor infiltrating CD8 T cells correlate with clinical responses to nivo or nivo + bev, but not to nivo + ipi; 2) tumor IFN pathway gene expression correlates with responses; and 3) PD-L1 status, tumor mutation or mutation burden, neoantigens did not correlate with response. Conclusions: IC therapy plus CS is safe and beneficial to patients with MRCC and therefore, warrants testing, along with a few correlative biomarkers, in a larger phase 3 trial. Clinical trial information: NCT 02210117.